231 results on '"Tintore, M."'
Search Results
2. Consenso de expertos sobre el uso de alemtuzumab en la práctica clínica diaria en España
- Author
-
Meca-Lallana, J.E., Fernández-Prada, M., García Vázquez, E., Moreno Guillén, S., Otero Romero, S., Rus Hidalgo, M., Villar Guimerans, L.M., Eichau Madueño, S., Fernández Fernández, Ó., Izquierdo Ayuso, G., Álvarez Cermeño, J.C., Arnal García, C., Arroyo González, R., Brieva Ruiz, L., Calles Hernández, C., García Merino, A., González Platas, M., Hernández Pérez, M.Á., Moral Torres, E., Olascoaga Urtaza, J., Oliva-Nacarino, P., Oreja-Guevara, C., Ortiz Castillo, R., Oterino, A., Prieto González, J.M., Ramió-Torrentá, L., Rodríguez-Antigüedad, A., Saiz, A., Tintoré, M., and Montalbán Gairin, X.
- Published
- 2022
- Full Text
- View/download PDF
3. Gadolinium-enhanced brain lesions in multiple sclerosis relapse
- Author
-
Martín-Aguilar, L., Presas-Rodriguez, S., Rovira, À., Capellades, J., Massuet-Vilamajó, A., Ramió-Torrentà, L., Tintoré, M., Brieva-Ruiz, L., Moral, E., Cano-Orgaz, A., Blanco, Y., Batlle-Nadal, J., Carmona, O., Gea, M., Hervás-García, J.V., and Ramo-Tello, C.
- Published
- 2022
- Full Text
- View/download PDF
4. Leadership in times of crisis. School principals facing COVID-19
- Author
-
Ramos-Pla, A., Tintoré, M., and del Arco, I.
- Published
- 2021
- Full Text
- View/download PDF
5. Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement
- Author
-
Otero-Romero, S., Rodríguez-García, J., Vilella, A., Ara, J.R., Brieva, L., Calles, C., Carmona, O., Casanova, V., Costa-Frossard, L., Eichau, S., García-Merino, J.A., Garcia-Vidal, C., González-Platas, M., Llaneza, M., Martínez-Ginés, M., Meca-Lallana, J.E., Prieto, J.M., Rodríguez-Antigüedad, A., Tintoré, M., Blanco, Y., and Moral, E.
- Published
- 2021
- Full Text
- View/download PDF
6. Recomendaciones para la vacunación en pacientes con esclerosis múltiple candidatos a terapias inmunosupresoras: documento de consenso español
- Author
-
Otero-Romero, S., Rodríguez-García, J., Vilella, A., Ara, J.R., Brieva, L., Calles, C., Carmona, O., Casanova, V., Costa-Frossard, L., Eichau, S., García-Merino, J.A., Garcia-Vidal, C., González-Platas, M., Llaneza, M., Martínez-Ginés, M., Meca-Lallana, J.E., Prieto, J.M., Rodríguez-Antigüedad, A., Tintoré, M., Blanco, Y., and Moral, E.
- Published
- 2021
- Full Text
- View/download PDF
7. Treatment of MOG antibody associated disorders: results of an international survey
- Author
-
Whittam, D. H., Karthikeayan, V., Gibbons, E., Kneen, R., Chandratre, S., Ciccarelli, O., Hacohen, Y., de Seze, J., Deiva, K., Hintzen, R. Q., Wildemann, B., Jarius, S., Kleiter, I., Rostasy, K., Huppke, P., Hemmer, B., Paul, F., Aktas, O., Pröbstel, A. K., Arrambide, G., Tintore, M., Amato, M. P., Nosadini, M., Mancardi, M. M., Capobianco, M., Illes, Z., Siva, A., Altintas, A., Akman-Demir, G., Pandit, L., Apiwattankul, M., Hor, J. Y., Viswanathan, S., Qiu, W., Kim, H. J., Nakashima, I., Fujihara, K., Ramanathan, S., Dale, R. C., Boggild, M., Broadley, S., Lana-Peixoto, M. A., Sato, D. K., Tenembaum, S., Cabre, P., Wingerchuk, D. M., Weinshenker, B. G., Greenberg, B., Matiello, M., Klawiter, E. C., Bennett, J. L., Wallach, A. I., Kister, I., Banwell, B. L., Traboulsee, A., Pohl, D., Palace, J., Leite, M. I., Levy, M., Marignier, R., Solomon, T., Lim, M., Huda, S., and Jacob, A.
- Published
- 2020
- Full Text
- View/download PDF
8. Validation of a New Semiautomated Segmentation Pipeline Based on the Spinal Cord Toolbox DeepSeg Algorithm to Estimate the Cervical Canal Area.
- Author
-
Mongay-Ochoa, N., Pareto, D., Alberich, M., Tintore, M., Montalban, X., Rovira, À., and Sastre-Garriga, J.
- Published
- 2023
- Full Text
- View/download PDF
9. Lesiones cerebrales captantes de gadolinio en el brote de los pacientes con esclerosis múltiple
- Author
-
Martin-Aguilar, L, Presas-Rodriguez, S, Rovira, A, Capellades, J, Massuet-Vilamajo, A, Ramio-Torrenta, L, Tintore, M, Brieva-Ruiz, L, Moral, E, Cano-Orgaz, A, Blanco, Y, Batlle-Nadal, J, Carmona, O, Gea, M, Hervas-Garcia, JV, Ramo-Tello, C, Institut Català de la Salut, [Martín-Aguilar L] Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. [Presas-Rodriguez S] Multiple Sclerosis Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. [Rovira À] Secció de Neuroradiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Capellades J] Neuroradiology Department, Hospital del Mar, Barcelona, Spain. [Massuet-Vilamajó A] Neuroradiology Section, Diagnostic Imaging Institute, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain. [Ramió-Torrentà L] Multiple Sclerosis Unit, Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain. [Tintoré M] Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Brote ,Multiple Sclerosis ,Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] ,Gadolinium ,Gadolinium enhancement ,Other subheadings::Other subheadings::/drug therapy [Other subheadings] ,Nervous System::Central Nervous System::Brain [ANATOMY] ,sistema nervioso::sistema nervioso central::encéfalo [ANATOMÍA] ,Methylprednisolone ,Lesiones captantes de gadolinio ,Cervell - Imatgeria per ressonància magnètica ,Recurrence ,Resonancia magnética ,Materials Chemistry ,Humans ,Relapse ,Other subheadings::Other subheadings::/diagnostic imaging [Other subheadings] ,Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis [DISEASES] ,Brain ,Otros calificadores::Otros calificadores::/diagnóstico por imagen [Otros calificadores] ,Magnetic Resonance Imaging ,Esclerosis múltiple ,enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple [ENFERMEDADES] ,Neurology (clinical) ,Esclerosi múltiple - Tractament ,MRI - Abstract
Esclerosis múltiple; Brote; Resonancia magnética Esclerosi múltiple; Brot; Imatge per ressonància magnètica Multiple sclerosis; Outbreak; Magnetic resonance imaging Objective To study the clinico-radiological paradox in multiple sclerosis (MS) relapse by analyzing the number and location of gadolinium-enhanced (Gd+) lesions on brain MRI before methylprednisolone (MP) treatment. Methods We analyzed brain MRI from 90 relapsed MS patients in two Phase IV multicenter double-blind randomized clinical trials that showed the noninferiority of different routes and doses of MP administration. A 1.5- or 3-T brain MRI was performed at baseline before MP treatment and within 15 days of symptom onset. The number and location of Gd+ lesions were analyzed. Associations were studied using univariate analysis. Results Sixty-two percent of patients had at least 1 Gd+ brain lesion; the median number was 1 (interquartile range 0–4), and 41% of patients had 2 or more lesions. The most frequent location of Gd+ lesions was subcortical (41.4%). Gd+ brain lesions were found in 71.4% of patients with brainstem-cerebellum symptoms, 57.1% with spinal cord symptoms and 55.5% with optic neuritis (ON). Thirty percent of patients with brain symptoms did not have Gd+ lesions, and only 43.6% of patients had symptomatic Gd+ lesions. The univariate analysis showed a negative correlation between age and the number of Gd+ lesions (p = 0.002). Conclusion Most patients with relapse showed several Gd+ lesions on brain MRI, even when the clinical manifestation was outside of the brain. Our findings illustrate the clinico-radiological paradox in MS relapse and support the value of brain MRI in this scenario. Objetivo Estudiar la paradoja clínico-radiológica en el brote de la esclerosis múltiple (EM) mediante el análisis de lesiones captantes de gadolinio (Gd+) en la RM cerebral antes del tratamiento con metilprednisolona (MP). Métodos Analizamos la RM cerebral basal de 90 pacientes con EM en brote de 2 ensayos clínicos aleatorizados multicéntricos fase IV que demostraron la no inferioridad de diferentes vías y dosis de MP, realizadas antes del tratamiento con MP y en los 15 días siguientes a la aparición de los síntomas. Se analizaron el número y la localización de las lesiones Gd+. Se estudiaron las asociaciones mediante análisis univariado. Resultados El 62% de los pacientes tenía al menos una lesión Gd+ cerebral y el 41% de los pacientes tenía 2 o más lesiones. La localización más frecuente fue la subcortical (41,4%). Se encontraron lesiones Gd+ cerebrales en el 71,4% de los pacientes con síntomas de tronco cerebral o cerebelo, en el 57,1% con síntomas medulares y en el 55,5% con neuritis óptica. El 30% de los pacientes con síntomas cerebrales no tenían lesiones Gd+ y sólo el 4,.6% de los pacientes tenían lesiones Gd+ sintomáticas. El análisis univariante mostró una correlación negativa entre la edad y el número de lesiones Gd+ (p = 0,002). Conclusiones La mayoría de los pacientes en brote mostraron varias lesiones Gd+ en la RM cerebral, incluso cuando la manifestación clínica fue medular u óptica. Nuestros hallazgos ilustran la paradoja clínico-radiológica en el brote de la EM y apoyan el valor de la RM cerebral en este escenario. This work was supported in part by the Ministry of Health of Spain (grant numbers EC07/90278 and EC11/132) and personal grant Rio Hortega CM19/00042 to LMA.
- Published
- 2022
10. Natalizumab for relapsing-remitting multiple sclerosis
- Author
-
Horga, A. and Tintoré, M.
- Published
- 2011
- Full Text
- View/download PDF
11. Natalizumab para la esclerosis múltiple remitente-recurrente
- Author
-
Horga, A. and Tintoré, M.
- Published
- 2011
- Full Text
- View/download PDF
12. P.048 International MAGNIMS-CMSC-NAIMS consensus recommendations on the use of standardized MRI in MS
- Author
-
Traboulsee, A, primary, Wattjes, M, additional, Ciccarelli, O, additional, Reich, D, additional, Banwell, B, additional, de Stefano, N, additional, Enzinger, C, additional, Fazekas, F, additional, Filippi, M, additional, Frederiksen, J, additional, Gasperini, C, additional, Hacohen, Y, additional, Kappos, L, additional, Li, DK, additional, Mankad, K, additional, Montalban, X, additional, Newsome, S, additional, Oh, J, additional, Palace, J, additional, Rocca, M, additional, Sastre-Garriga, J, additional, Tintore, M, additional, Vrenken, H, additional, Yours, T, additional, Barkhof, F, additional, and Rovira, A, additional
- Published
- 2021
- Full Text
- View/download PDF
13. Recommendations for using and interpreting magnetic resonance imaging in multiple sclerosis
- Author
-
Rovira, A., Tintoré, M., Álvarez-Cermeño, J.C., Izquierdo, G., and Prieto, J.M.
- Published
- 2010
- Full Text
- View/download PDF
14. Recomendaciones para la utilización e interpretación de los estudios de resonancia magnética en la esclerosis múltiple
- Author
-
Rovira, A., Tintoré, M., Álvarez-Cermeño, J.C., Izquierdo, G., and Prieto, J.M.
- Published
- 2010
- Full Text
- View/download PDF
15. Myelin-oligodendrocyte glycoprotein antibody-associated disease
- Author
-
Marignier, R. Hacohen, Y. Cobo-Calvo, A. Pröbstel, A.-K. Aktas, O. Alexopoulos, H. Amato, M.-P. Asgari, N. Banwell, B. Bennett, J. Brilot, F. Capobianco, M. Chitnis, T. Ciccarelli, O. Deiva, K. De Sèze, J. Fujihara, K. Jacob, A. Kim, H.J. Kleiter, I. Lassmann, H. Leite, M.-I. Linington, C. Meinl, E. Palace, J. Paul, F. Petzold, A. Pittock, S. Reindl, M. Sato, D.K. Selmaj, K. Siva, A. Stankoff, B. Tintore, M. Traboulsee, A. Waters, P. Waubant, E. Weinshenker, B. Derfuss, T. Vukusic, S. Hemmer, B.
- Abstract
Myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently identified autoimmune disorder that presents in both adults and children as CNS demyelination. Although there are clinical phenotypic overlaps between MOGAD, multiple sclerosis, and aquaporin-4 antibody-associated neuromyelitis optica spectrum disorder (NMOSD) cumulative biological, clinical, and pathological evidence discriminates between these conditions. Patients should not be diagnosed with multiple sclerosis or NMOSD if they have anti-MOG antibodies in their serum. However, many questions related to the clinical characterisation of MOGAD and pathogenetic role of MOG antibodies are still unanswered. Furthermore, therapy is mainly based on standard protocols for aquaporin-4 antibody-associated NMOSD and multiple sclerosis, and more evidence is needed regarding how and when to treat patients with MOGAD. © 2021 Elsevier Ltd
- Published
- 2021
16. The Multiple Sclerosis Data Alliance Catalogue: Enabling Web-Based Discovery of Metadata from Real-World Multiple Sclerosis Data Sources.
- Author
-
Geys, L, Parciak, T, Pirmani, A, McBurney, R, Schmidt, H, Malbaša, T, Ziemssen, T, Bergmann, A, Rojas, JI, Cristiano, E, García-Merino, JA, Fernández, Ó, Kuhle, J, Gobbi, C, Delmas, A, Simpson-Yap, S, Nag, N, Yamout, B, Steinemann, N, Seeldrayers, P, Dubois, B, van der Mei, I, Stahmann, A, Drulovic, J, Pekmezovic, T, Brola, W, Tintore, M, Kalkers, N, Ivanov, R, Zakaria, M, Naseer, MA, Van Hecke, W, Grigoriadis, N, Boziki, M, Carra, A, Pawlak, MA, Dobson, R, Hellwig, K, Gallagher, A, Leocani, L, Dalla Costa, G, de Carvalho Sousa, NA, Van Wijmeersch, B, Peeters, LM, Geys, L, Parciak, T, Pirmani, A, McBurney, R, Schmidt, H, Malbaša, T, Ziemssen, T, Bergmann, A, Rojas, JI, Cristiano, E, García-Merino, JA, Fernández, Ó, Kuhle, J, Gobbi, C, Delmas, A, Simpson-Yap, S, Nag, N, Yamout, B, Steinemann, N, Seeldrayers, P, Dubois, B, van der Mei, I, Stahmann, A, Drulovic, J, Pekmezovic, T, Brola, W, Tintore, M, Kalkers, N, Ivanov, R, Zakaria, M, Naseer, MA, Van Hecke, W, Grigoriadis, N, Boziki, M, Carra, A, Pawlak, MA, Dobson, R, Hellwig, K, Gallagher, A, Leocani, L, Dalla Costa, G, de Carvalho Sousa, NA, Van Wijmeersch, B, and Peeters, LM
- Abstract
BACKGROUND: One of the major objectives of the Multiple Sclerosis Data Alliance (MSDA) is to enable better discovery of multiple sclerosis (MS) real-world data (RWD). METHODS: We implemented the MSDA Catalogue, which is available worldwide. The current version of the MSDA Catalogue collects descriptive information on governance, purpose, inclusion criteria, procedures for data quality control, and how and which data are collected, including the use of e-health technologies and data on collection of COVID-19 variables. The current cataloguing procedure is performed in several manual steps, securing an effective catalogue. RESULTS: Herein we summarize the status of the MSDA Catalogue as of January 6, 2021. To date, 38 data sources across five continents are included in the MSDA Catalogue. These data sources differ in purpose, maturity, and variables collected, but this landscaping effort shows that there is substantial alignment on some domains. The MSDA Catalogue shows that personal data and basic disease data are the most collected categories of variables, whereas data on fatigue measurements and cognition scales are the least collected in MS registries/cohorts. CONCLUSIONS: The Web-based MSDA Catalogue provides strategic overview and allows authorized end users to browse metadata profiles of data cohorts and data sources. There are many existing and arising RWD sources in MS. Detailed cataloguing of MS RWD is a first and useful step toward reducing the time needed to discover MS RWD sets and promoting collaboration.
- Published
- 2021
17. A search for new MRI criteria for dissemination in space in subjects with a clinically isolated syndrome
- Author
-
Korteweg, T., Tintore, M., Uitdehaag, B. M. J., Knol, D. L., Vrenken, H., Rovira, A., Frederiksen, J., Miller, D. H., Fernando, K., Filippi, M., Agosta, F., Rocca, M. A., Fazekas, F., Enzinger, C., Parry, A., Polman, C. H., Montalban, X., and Barkhof, F.
- Published
- 2009
- Full Text
- View/download PDF
18. MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain: A review of reported findings
- Author
-
Seewann, A., Enzinger, C., Filippi, M., Barkhof, F., Rovira, A., Gass, A., Miller, D., Montalban, X., Thompson, A., Yousry, T., Tintore, M., de Stefano, N., Palace, J., Rovaris, M., Polman, C., Fazekas, F., and for the MAGNIMS network
- Published
- 2008
- Full Text
- View/download PDF
19. Radiologically Isolated Syndrome: 10-Year Risk Estimate of a Clinical Event
- Author
-
Lebrun-Frenay, C., Kantarci, O., Siva, A., Sormani, M. P., Pelletier, D., Okuda, D. T., Azevedo, C., Amato, M. P., Bensa, C., Berger, E., Brochet, B., Ciron, J., Cohen, M., Inglese, M., Keegan, B. M., Labauge, P., Laplaud, D. -A., Le Page, E., Louapre, C., Makhani, N., Mathey, G., Mondot, L., Montalban, X., Pelletier, J., de Seze, J., Destefano, N., Thouvenot, E., Tintore, M., Tutuncuoglu, M., Uygunoglu, U., Vermersch, P., Weinshenker, B., and Zeydan, B.
- Subjects
0301 basic medicine ,Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Multiple Sclerosis ,Time Factors ,Adolescent ,Journal Club ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Risk Factors ,medicine ,Humans ,Young adult ,Child ,Event (probability theory) ,Aged ,medicine.diagnostic_test ,Clinical events ,business.industry ,Proportional hazards model ,Multiple sclerosis ,Magnetic resonance imaging ,Middle Aged ,medicine.disease ,Demyelinating Diseases ,Female ,Magnetic Resonance Imaging ,Disease Progression ,030104 developmental biology ,Risk Estimate ,Neurology ,Neurology (clinical) ,business ,030217 neurology & neurosurgery ,Cohort study - Abstract
Objective We have previously identified male sex, younger age, and the presence of spinal cord lesions as independent factors that increase the 5-year risk for evolution from radiologically isolated syndrome (RIS) to multiple sclerosis. Here, we investigate risk factors for the development of a clinical event using a 10-year, multinational, retrospectively identified RIS dataset. Methods RIS subjects were identified according to 2009 RIS criteria and followed longitudinally as part of a worldwide cohort study. We analyzed data from 21 individual databases from 5 different countries. Associations between clinical and magnetic resonance imaging (MRI) characteristics and the risk of developing a first clinical event were determined using multivariate Cox regression models. Results Additional follow-up data were available in 277 of 451 RIS subjects (86% female). The mean age at RIS diagnosis was 37.2 years (range, 11-74 years), with a median clinical follow-up of 6.7 years. The cumulative probability of a first clinical event at 10 years was 51.2%. Age, positive cerebrospinal fluid for oligoclonal bands, infratentorial lesions on MRI, and spinal cord lesions, were baseline independent predictors associated with a subsequent clinical event. The presence of gadolinium-enhanced lesions during follow-up was also associated with the risk of a seminal event. The reason for MRI and gadolinium-enhancing lesions at baseline did not influence the risk of a subsequent clinical event. Interpretation Approximately half of all individuals with RIS experience a first clinical event within 10 years of the index MRI. The identification of independent predictors of risk for symptom onset may guide education and clinical management of individuals with RIS. ANN NEUROL 2020;88:407-417.
- Published
- 2020
20. Aggressive multiple sclerosis (2): Treatment
- Author
-
Arrambide, G., Iacobaeus, E., Amato, M. P., Derfuss, T., Vukusic, S., Hemmer, B., Brundin, L., Tintore, M., Berger, J., Boyko, A., Brinar, V., Brownlee, W., Ciccarelli, O., Coles, A., Correale, J., Cutter, G., Edan, G., Evangelou, N., Fernandez, O., Frederiksen, J., Gold, R., Hacohen, Y., Hartung, H. -P., Hellwig, K., Hillert, J., Imitola, J., Kalincik, T., Kappos, L., Khoury, S., Kim, H. J., Havrdova, E. K., Liblau, R., Lycke, J., Montalban, X., Muraro, P., Reingold, S., Schmierer, K., Sellebjerg, F., Sorensen, P. S., Solari, A., Sormani, M. P., Thompson, A., Trapp, B., Tremlett, H., Trojano, M., Tur, C., Uccelli, A., van Pesch, V., and Waubant, E.
- Subjects
Aggressive ,medicine.medical_specialty ,Treatment response ,relapsing–remitting ,Disease ,Permanent disability ,multiple sclerosis ,disability ,highly active ,treatment response ,Multiple sclerosis ,03 medical and health sciences ,0302 clinical medicine ,2018 ECTRIMS Focused Workshop Group ,medicine ,Relapsing-remitting ,030212 general & internal medicine ,Intensive care medicine ,Highly active ,Therapeutic window ,Neurology & Neurosurgery ,Disability ,business.industry ,1103 Clinical Sciences ,medicine.disease ,ddc ,Natural history ,Neurology ,Relapsing remitting ,Neurology (clinical) ,business ,1109 Neurosciences ,030217 neurology & neurosurgery ,Meeting Reviews - Abstract
Altres ajuts: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The workshop on which the manuscript is based was supported in its entirety by the European Committee on Treatment and Research in Multiple Sclerosis (ECTRIMS). The natural history of multiple sclerosis (MS) is highly heterogeneous. A subgroup of patients has what might be termed aggressive MS. These patients may have frequent, severe relapses with incomplete recovery and are at risk of developing greater and permanent disability at the earlier stages of the disease. Their therapeutic window of opportunity may be narrow, and while it is generally considered that they will benefit from starting early with a highly efficacious treatment, a unified definition of aggressive MS does not exist and data on its treatment are largely lacking. Based on discussions at an international focused workshop sponsored by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), we review our current knowledge about treatment of individuals with aggressive MS. We analyse the available evidence, identify gaps in knowledge and suggest future research needed to fill those gaps. A companion paper details the difficulties in developing a consensus about what defines aggressive MS.
- Published
- 2020
21. Aggressive multiple sclerosis (1) : Towards a definition of the phenotype
- Author
-
Iacobaeus, E., Arrambide, G., Amato, M. P., Derfuss, T., Vukusic, S., Hemmer, B., Tintore, M., Brundin, L., Berger, J., Boyko, A., Brinar, V., Brownlee, W., Ciccarelli, O., Coles, A., Correale, J., Cutter, G., Edan, G., Evangelou, N., Fernandez, O., Frederiksen, J., Gold, R., Hacohen, Y., Hartung, H. -P., Hellwig, K., Hillert, J., Imitola, J., Kalincik, T., Kappos, L., Khoury, S., Kim, H. J., Havrdova, E. K., Liblau, R., Lycke, J., Montalban, X., Muraro, P., Reingold, S., Schmierer, K., Sellebjerg, F., Sorensen, P. S., Solari, A., Sormani, M. P., Thompson, A., Trapp, B., Tremlett, H., Trojano, M., Tur, C., Uccelli, A., van Pesch, V., Waubant, E., UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, and UCL - (SLuc) Service de neurologie
- Subjects
Disease subtype ,Aggressive ,medicine.medical_specialty ,Severe disease ,Aggressive disease ,multiple sclerosis ,Relapsing/remitting ,Multiple sclerosis ,03 medical and health sciences ,0302 clinical medicine ,disability ,highly active ,observational studies ,relapsing/remitting ,2018 ECTRIMS Focused Workshop Group ,medicine ,Intensive care medicine ,Secondary progressive ,Highly active ,Observational studies ,030304 developmental biology ,0303 health sciences ,Neurology & Neurosurgery ,Disability ,business.industry ,1103 Clinical Sciences ,medicine.disease ,Phenotype ,Additional research ,ddc ,Neurology ,Observational study ,Neurology (clinical) ,1109 Neurosciences ,business ,030217 neurology & neurosurgery ,Meeting Reviews - Abstract
Altres ajuts: The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: The workshop on which the manuscript is based was supported in its entirety by the European Committee on Treatment and Research in Multiple Sclerosis (ECTRIMS). While the major phenotypes of multiple sclerosis (MS) and relapsing-remitting, primary and secondary progressive MS have been well characterized, a subgroup of patients with an active, aggressive disease course and rapid disability accumulation remains difficult to define and there is no consensus about their management and treatment. The current lack of an accepted definition and treatment guidelines for aggressive MS triggered a 2018 focused workshop of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) on aggressive MS. The aim of the workshop was to discuss approaches on how to describe and define the disease phenotype and its treatments. Unfortunately, it was not possible to come to consensus on a definition because of unavailable data correlating severe disease with imaging and molecular biomarkers. However, the workshop highlighted the need for future research needed to define this disease subtype while also focusing on its treatment and management. Here, we review previous attempts to define aggressive MS and present characteristics that might, with additional research, eventually help characterize it. A companion paper summarizes data regarding treatment and management.
- Published
- 2020
22. Sex effects across the lifespan in women with multiple sclerosis
- Author
-
Krysko, KM, Graves, JS, Dobson, R, Altintas, A, Amato, MP, Bernard, J, Bonavita, S, Bove, R, Cavalla, P, Clerico, M, Corona, T, Doshi, A, Fragoso, Y, Jacobs, D, Jokubaitis, V, Landi, D, Llamosa, G, Longbrake, EE, Maillart, E, Marta, M, Midaglia, L, Shah, S, Tintore, M, van der Walt, A, Voskuhl, R, Wang, Y, Zabad, RK, Zeydan, B, Houtchens, M, Hellwig, K, Krysko, KM, Graves, JS, Dobson, R, Altintas, A, Amato, MP, Bernard, J, Bonavita, S, Bove, R, Cavalla, P, Clerico, M, Corona, T, Doshi, A, Fragoso, Y, Jacobs, D, Jokubaitis, V, Landi, D, Llamosa, G, Longbrake, EE, Maillart, E, Marta, M, Midaglia, L, Shah, S, Tintore, M, van der Walt, A, Voskuhl, R, Wang, Y, Zabad, RK, Zeydan, B, Houtchens, M, and Hellwig, K
- Abstract
Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating central nervous system disorder that is more common in women, with onset often during reproductive years. The female:male sex ratio of MS rose in several regions over the last century, suggesting a possible sex by environmental interaction increasing MS risk in women. Since many with MS are in their childbearing years, family planning, including contraceptive and disease-modifying therapy (DMT) counselling, are important aspects of MS care in women. While some DMTs are likely harmful to the developing fetus, others can be used shortly before or until pregnancy is confirmed. Overall, pregnancy decreases risk of MS relapses, whereas relapse risk may increase postpartum, although pregnancy does not appear to be harmful for long-term prognosis of MS. However, ovarian aging may contribute to disability progression in women with MS. Here, we review sex effects across the lifespan in women with MS, including the effect of sex on MS susceptibility, effects of pregnancy on MS disease activity, and management strategies around pregnancy, including risks associated with DMT use before and during pregnancy, and while breastfeeding. We also review reproductive aging and sexual dysfunction in women with MS.
- Published
- 2020
23. Aggressive multiple sclerosis (2): Treatment.
- Author
-
Arrambide, G, Iacobaeus, E, Amato, MP, Derfuss, T, Vukusic, S, Hemmer, B, Brundin, L, Tintore, M, 2018 ECTRIMS Focused Workshop Group, Arrambide, G, Iacobaeus, E, Amato, MP, Derfuss, T, Vukusic, S, Hemmer, B, Brundin, L, Tintore, M, and 2018 ECTRIMS Focused Workshop Group
- Abstract
The natural history of multiple sclerosis (MS) is highly heterogeneous. A subgroup of patients has what might be termed aggressive MS. These patients may have frequent, severe relapses with incomplete recovery and are at risk of developing greater and permanent disability at the earlier stages of the disease. Their therapeutic window of opportunity may be narrow, and while it is generally considered that they will benefit from starting early with a highly efficacious treatment, a unified definition of aggressive MS does not exist and data on its treatment are largely lacking. Based on discussions at an international focused workshop sponsored by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), we review our current knowledge about treatment of individuals with aggressive MS. We analyse the available evidence, identify gaps in knowledge and suggest future research needed to fill those gaps. A companion paper details the difficulties in developing a consensus about what defines aggressive MS.
- Published
- 2020
24. Aggressive multiple sclerosis (1): Towards a definition of the phenotype.
- Author
-
Iacobaeus, E, Arrambide, G, Amato, MP, Derfuss, T, Vukusic, S, Hemmer, B, Tintore, M, Brundin, L, 2018 ECTRIMS Focused Workshop Group, Iacobaeus, E, Arrambide, G, Amato, MP, Derfuss, T, Vukusic, S, Hemmer, B, Tintore, M, Brundin, L, and 2018 ECTRIMS Focused Workshop Group
- Abstract
While the major phenotypes of multiple sclerosis (MS) and relapsing-remitting, primary and secondary progressive MS have been well characterized, a subgroup of patients with an active, aggressive disease course and rapid disability accumulation remains difficult to define and there is no consensus about their management and treatment. The current lack of an accepted definition and treatment guidelines for aggressive MS triggered a 2018 focused workshop of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) on aggressive MS. The aim of the workshop was to discuss approaches on how to describe and define the disease phenotype and its treatments. Unfortunately, it was not possible to come to consensus on a definition because of unavailable data correlating severe disease with imaging and molecular biomarkers. However, the workshop highlighted the need for future research needed to define this disease subtype while also focusing on its treatment and management. Here, we review previous attempts to define aggressive MS and present characteristics that might, with additional research, eventually help characterize it. A companion paper summarizes data regarding treatment and management.
- Published
- 2020
25. Interferon beta in relapsing--remitting multiple sclerosis; An eight years experience in a specialist multiple sclerosis centre
- Author
-
Rio, J., Tintore, M., Nos, C., Tellez, N., Galan, I., and Montalban, X.
- Subjects
Interferon beta -- Dosage and administration ,Interferon beta -- Health aspects ,Multiple sclerosis -- Drug therapy ,Multiple sclerosis -- Research ,Health - Abstract
Byline: J. Rio (1), M. Tintore (1), C. Nos (1), N. Tellez (1), I. Galan (1), X. Montalban (1) Keywords: multiple sclerosis; interferon beta; observational study Abstract: Background and objective Long--term observational studies may provide additional information about the behaviour of different drugs in the post--marketing period. We present the data of our cohort of relapsing--remitting multiple sclerosis (RRMS) patients treated with interferon beta (IFN[beta]). Methods We analysed RRMS patients followed for at least 2 years. From 1995, we initiated therapy with IFN[beta].As they became available, patients were allocated to one of the IFNs at standard doses (IFN[beta]--1b, IFN[beta]--1a i. m. or IFN[beta]--1a s. c.). Each patient was included in a follow--up protocol containing demographic and baseline clinical data. Results Between 1995 and 2004, 382 patients have completed at least 2 years of follow--up. Significant differences at entry were observed. Patients on IFN[beta]--1b had a higher disease activity and disability at baseline than those on IFN[beta]--1a i. m. or IFN[beta]--1a s. c. A significant reduction in the relapse rate was observed for the three drugs (70 % for IFN[beta]--1b, 64% for IFN[beta]--1a i. m. and 74 % for IFN[beta]--1a s. c.). We observed a sustained progression of disability in 11% of patients on IFN[beta]--1b, 17% on IFN[beta]--1a i. m. and 19% on IFN[beta]--1a s. c. and at four years of follow--up in 24% of patients on IFN[beta]--1b, 23% on IFN[beta]--1a i. m. and 35% on IFN[beta]--1a s. c. No unexpected major adverse events were observed with any of the drugs. Conclusions Interferon beta is safe and well tolerated. The various registered interferon beta drugs provide a comparable efficacy in a large non--selected cohort of RRMS patients. Author Affiliation: (1) 2a planta, EUI Unitat de Neuroimmunologia Clinica, Hospital Universitario Vall d'Hebron, Psg.Vall d'Hebron 119-120, 08035, Barcelona, Spain Article History: Registration Date: 01/01/2005 Received Date: 28/04/2004 Accepted Date: 08/11/2004 Online Date: 18/03/2005
- Published
- 2005
26. Optical coherence tomography measures correlate with brain and spinal cord atrophy and multiple sclerosis disease‐related disability
- Author
-
Vidal‐Jordana, A., primary, Pareto, D., additional, Cabello, S., additional, Alberich, M., additional, Rio, J., additional, Tintore, M., additional, Auger, C., additional, Montalban, X., additional, Rovira, A., additional, and Sastre‐Garriga, J., additional
- Published
- 2020
- Full Text
- View/download PDF
27. The role of pregnancy in long term prognosis
- Author
-
Tintore, M., primary
- Published
- 2019
- Full Text
- View/download PDF
28. Multiple sclerosis
- Author
-
Tintore, M., primary
- Published
- 2019
- Full Text
- View/download PDF
29. Information searching for multiple sclerosis
- Author
-
Jorda, M, Nos, C, Duran, I, Rio, J, Tintore, M, and Montalban, X
- Published
- 1998
30. Recurrent Guillain-Barre syndrome and CNS demyelination
- Author
-
Rio, J, Nos, C, Tintore, M, Marzo, M E, and Montalban, X
- Published
- 1997
31. High dose intravenous immunoglobulin does not improve abnormalities in the blood-brain barrier during acute relapse of multiple sclerosis
- Author
-
Nos, C., Comabella, M., Tintore, M., Rio, J., Codina, A., Montalban, X., and Rovira, A.
- Published
- 1996
32. Antibodies against endothelial cells in patients with multiple sclerosis
- Author
-
Tintore, M., Fernandez, A. L., Rovira, A., Martinez, X., Direskeneli, H., Khamashta, M., Schwartz, S., Codina, A., and Montalban, X.
- Published
- 1996
33. Clinically definite multiple sclerosis after radiological Schilder-like onset
- Author
-
Sastre-Garriga, J., Rovira, A., Rio, J., Tintore, M., Grive, E., and Montalban, X.
- Subjects
Multiple sclerosis -- Research ,Health - Abstract
Byline: J. Sastre-Garriga (1), A. Rovira (2), J. Rio (1), M. Tintore (1), E. Grive (2), X. Montalban (1) Author Affiliation: (1) Unitat de Neuroimmunologia Clinica Servei de Neurologia, Escola d'Infermeria, 2a planta. H.Vall d'Hebron Passeig de la Vall d'Hebron 119--129, 08035, Barcelona, Spain (2) Unitat de Ressonancia Magnetica, Hospital Vall d'Hebron, Barcelona, Spain Article History: Received Date: 15/11/2002 Accepted Date: 20/02/2003
- Published
- 2003
34. Gender Inequities in the Multiple Sclerosis Community: A Call for Action
- Author
-
Waubant, E, Amezcua, L, Sicotte, N, Hellwig, K, Krupp, L, Weinstock-Guttman, B, Yeh, A, Lucas, RM, Longbrake, EE, Yadav, V, Rensel, M, Mar, S, Hersh, C, Block, V, Zipp, F, Han, MH, Spain, R, Kelland, EE, Charvet, L, Dimitri, D, Papeix, C, Cross, AH, Inglese, M, Amato, MP, Airas, L, Leray, E, Sormani, MP, Van der Walt, A, Vukusic, S, Castillo-Trivino, T, Tenembaum, S, Ciccarelli, O, Bommarito, G, Petracca, M, Celius, EG, Carson, MJ, Hua, LH, Van der Mei, I, Lubetzki, C, Jokubaitis, V, Trojano, M, Voskuhl, R, Tintore, M, Harbo, H, Asgari, N, Piccio, L, Burton, JM, Tremlett, H, Goldman, MD, Michel, L, Zhang, Y, Bove, R, Quandt, JA, Costello, F, Ionete, C, Lebrun-Frenay, C, Pakpoor, J, Bevan, C, Morrow, SA, Waldman, AT, Oh, J, Jacobs, D, Palace, J, Marrie, RA, Tiwari-Woodruff, SK, Metz, LM, Cortese, R, Chitnis, T, Benson, L, Benveniste, ET, Conway, J, Sand, IK, Murphy, JO, Kita, M, Riley, C, Goverman, JM, Langer-Gould, AM, Azevedo, CJ, Morales, IB, Barcellos, LF, Crabtree, E, Plummer, P, Shirani, A, Whartenby, K, Brilot-Turville, F, Kingwell, E, Coyle, P, Mowry, E, Zabad, R, Bielekova, B, Monson, N, Laule, C, Burnett, M, Schreiner, T, Grinspan, J, Dobson, R, Akassoglou, K, Graves, J, Gray, O, Smyth, P, Havrdova, EK, Preiningerova, JL, Banwell, B, Makhani, N, Lucchinetti, C, Arrambide, G, Maillart, E, Macklin, W, Gilmore, W, Waubant, E, Amezcua, L, Sicotte, N, Hellwig, K, Krupp, L, Weinstock-Guttman, B, Yeh, A, Lucas, RM, Longbrake, EE, Yadav, V, Rensel, M, Mar, S, Hersh, C, Block, V, Zipp, F, Han, MH, Spain, R, Kelland, EE, Charvet, L, Dimitri, D, Papeix, C, Cross, AH, Inglese, M, Amato, MP, Airas, L, Leray, E, Sormani, MP, Van der Walt, A, Vukusic, S, Castillo-Trivino, T, Tenembaum, S, Ciccarelli, O, Bommarito, G, Petracca, M, Celius, EG, Carson, MJ, Hua, LH, Van der Mei, I, Lubetzki, C, Jokubaitis, V, Trojano, M, Voskuhl, R, Tintore, M, Harbo, H, Asgari, N, Piccio, L, Burton, JM, Tremlett, H, Goldman, MD, Michel, L, Zhang, Y, Bove, R, Quandt, JA, Costello, F, Ionete, C, Lebrun-Frenay, C, Pakpoor, J, Bevan, C, Morrow, SA, Waldman, AT, Oh, J, Jacobs, D, Palace, J, Marrie, RA, Tiwari-Woodruff, SK, Metz, LM, Cortese, R, Chitnis, T, Benson, L, Benveniste, ET, Conway, J, Sand, IK, Murphy, JO, Kita, M, Riley, C, Goverman, JM, Langer-Gould, AM, Azevedo, CJ, Morales, IB, Barcellos, LF, Crabtree, E, Plummer, P, Shirani, A, Whartenby, K, Brilot-Turville, F, Kingwell, E, Coyle, P, Mowry, E, Zabad, R, Bielekova, B, Monson, N, Laule, C, Burnett, M, Schreiner, T, Grinspan, J, Dobson, R, Akassoglou, K, Graves, J, Gray, O, Smyth, P, Havrdova, EK, Preiningerova, JL, Banwell, B, Makhani, N, Lucchinetti, C, Arrambide, G, Maillart, E, Macklin, W, and Gilmore, W
- Published
- 2018
35. Epidemiology of neuromyelitis optica spectrum disorders in Catalonia: a population-based study
- Author
-
Sepulveda, M, Aldea, M, Escudero, D, Llufriu, S, Arrambide, G, Otero-Romero, S, Sastre-Garriga, J, Romero-Pinel, L, Martinez-Yelamos, S, Sola-Valls, N, Armangue, T, Sotoca, J, Escartin, A, Robles, R, Ramio-Torrenta, L, Presas, S, Ramo, C, Munteis, E, Pelayo, R, Gubieras, L, Brieva, L, Ortiz, N, Hervas, M, Mane-Martinez, MA, Cano, A, Vela, E, Tintore, M, Blanco, Y, Montalban, X, Graus, F, and Saiz, A
- Published
- 2017
36. Gut Microbiota Dysbiosis and Role of Probiotics in Infant Colic
- Author
-
Tintore M, Colome G, Espadaler J, and Santas J
- Subjects
Microbiology (medical) ,030219 obstetrics & reproductive medicine ,biology ,030206 dentistry ,Gut flora ,medicine.disease ,biology.organism_classification ,digestive system ,03 medical and health sciences ,0302 clinical medicine ,Infectious Diseases ,Immunology ,medicine ,Dysbiosis - Published
- 2017
37. To differentiate the indication to treat the clinically isolated syndrome on the bases of different clinical onsets. The subgroup analyses from a Cochrane meta-analysis
- Author
-
Marinella CLERICO, Faggiano, F., Palace, J., Tintore, M., and Durelli, L.
- Published
- 2016
38. Conversion from clinically isolated syndromes to multiple sclerosis: how could we prevent it? A Cochrane review of published trials
- Author
-
Marinella CLERICO, Faggiano, F., Rice, G., Palace, J., Tintore, M., and Durelli, L.
- Published
- 2016
39. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome
- Author
-
Disanto, G, Adiutori, R, Dobson, R, Martinelli, V, Costa, GD, Runia, T, Evdoshenko, E, Thouvenot, E, Trojano, M, Norgren, N, Teunissen, C, Kappos, L, Giovannoni, G, Kuhle, J, Bianchi, L, Topping, J, Bestwick, JP, Meier, UC, Lazareva, N, Iaffaldano, P, Direnzo, V, Khademi, M, Piehl, F, Comabella, M, Sombekke, M, Killestein, J, Hegen, H, Rauch, S, D'Alfonso, S, Alvarez-Cermeno, JC, Kleinova, P, Horakova, D, Roesler, R, Lauda, F, Llufriu, S, Avsar, T, Uygunoglu, U, Altintas, A, Saip, S, Menge, T, Rajda, C, Bergamaschi, R, Moll, N, Khalil, M, Marignier, R, Dujmovic, I, Larsson, H, Malmestrom, C, Scarpini, E, Fenoglio, C, Wergeland, S, Laroni, A, Annibali, V, Romano, S, Martinez, AD, Carra, A, Salvetti, M, Uccelli, A, Torkildsen, O, Myhr, K, Galimberti, D, Rejdak, K, Lycke, J, Frederiksen, JL, Drulovic, J, Confavreux, C, Brassat, D, Enzinger, C, Fuchs, S, Bosca, I, Pelletier, J, Picard, C, Colombo, E, Franciotta, D, Derfuss, T, Lindberg, RL, Yaldizli, O, Vecsei, L, Kieseier, BC, Hartung, HP, Villoslada, P, Siva, A, Saiz, A, Tumani, H, Havrdova, E, Villar, LM, Leone, M, Barizzone, N, Deisenhammer, F, Montalban, X, Tintore, M, Olsson, T, Lehmann, S, Castelnovo, G, Lapin, S, Hintzen, R, Furlan, R, Comi, G, Ramagopalan, SV, and Int Clinically Isolated Syndrome S
- Abstract
Background Neurofilament light chain (NfL) represents a promising biomarker for axonal injury. We present the first exploratory study on serum NfL in patients with a clinically isolated syndrome (CIS) and healthy controls. Methods We investigated serum NfL levels in 100 patients with CIS with a short conversion interval to clinically definite multiple sclerosis (MS) (fast converters (FC), median (IQR) conversion time: 110 days (79-139)); 98 patients with non-converting CIS (non-converters (NC), follow-up: 6.5 years (5.3-7.9)); and 92 healthy controls. Results NfL levels were higher in FC (24.1 pg/mL (13.5-51.8)) and NC (19.3 pg/mL (13.6-35.2)) than in healthy controls (7.9 pg/mL (5.6-17.2)) (OR=5.85; 95% CI 2.63 to 13.02; p=1.5x10(-5) and OR=7.03; 95% CI 2.85 to 17.34; p=2.3x10(-5), respectively). When grouping FC and NC, increased serum NfL concentration was also associated with increasing numbers of T2 hyperintense MRI lesions (OR=2.36; 95% CI 1.21 to 4.59; p=0.011), gadolinium-enhancing lesions (OR=2.69; 95% CI 1.13 to 6.41; p=0.026) and higher disability scores (OR=2.54; 95% CI 1.21 to 5.31; p=0.013) at CIS diagnosis. Conclusions If replicated in future studies, serum NfL may represent a reliable and easily accessible biomarker of early axonal damage in CIS and MS.
- Published
- 2016
40. [Review of the novelties from the 2014 ECTRIMS-ACTRIMS Joint Congress, presented at the 7th Post-ECTRIMS meeting (I)]
- Author
-
Fernandez O, Alvarez-Cermeno JC, Arroyo R, Brieva L, Calles-Hernandez MC, Casanova-Estruch B, Comabella M, Garcia-Merino JA, Ginestal R, Izquierdo G, Meca-Lallana JE, Mendibe-Bilbao MM, Montalban X, Munoz-Garcia D, Olascoaga J, Oliva-Nacarino P, Oreja-Guevara C, Ramio-Torrenta L, Romero-Pinel L, Rodriguez-Antiguedad A, Saiz A, Tintore M, and Grupo Post-Ectrims GP
- Subjects
ECTRIMS ,Multiple sclerosis ,Post-ECTRIMS ,Multiple Sclerosis ,Humans ,Congresses as Topic - Abstract
For the seventh year in a row the Post-ECTRIMS Meeting has been held in Madrid (Spain). Renowned specialists in multiple sclerosis and national leaders in this area have gathered once again to discuss the novelties presented at the 2014 ECTRIM-ACTRIMS World Congress. That meeting gave rise to this review, which will be published in two parts. One of the main conclusions in this first part is the deeper understanding of the genetic component of multiple sclerosis that we are acquiring, although it is still insufficient unless we bear in mind its interaction with the environmental risk factors of the disease or the impact of comorbidity and healthy habits on the patients' susceptibility and prognosis. In this respect, the authors insist on the fact that, in clinical practice, the cognitive and psychiatric disorders remain under-diagnosed and are rarely taken into account in clinical research. Yet, although scarce, the evidence we have points to the possible benefits of disease-modifying drugs and alternatives to treatment with selective serotonin reuptake inhibitors. Addressing the sub-populations in multiple sclerosis and variants of the disease enhances the importance of an early accurate diagnosis in order to offer patients a safer and more personalised prognosis and treatment. Paediatric multiple sclerosis is ideal for studying the risk factors of the disease but, given its low prevalence, the use of prospective studies raises a number of doubts and there is a preference for conducting collaborative studies.Revision de las novedades del congreso conjunto ECTRIMS-ACTRIMS 2014, presentadas en la VII Reunion Post-ECTRIMS (I).Por septimo año consecutivo se ha celebrado en Madrid (España) la Reunion Post-ECTRIMS. Reconocidos especialistas en esclerosis multiple y lideres de opinion nacionales se han reunido un año mas para exponer las novedades presentadas en el Congreso Mundial ECTRIMS-ACTRIMS 2014, y fruto de esa reunion se genera esta revision que sale publicada en dos partes. Como principales conclusiones de esta primera parte se destaca el mayor entendimiento del componente genetico de la esclerosis multiple al que estamos asistiendo, el cual no resulta suficiente si no se considera su interaccion con los factores ambientales de riesgo de la enfermedad, ni el impacto de la comorbilidad y de las conductas saludables en la susceptibilidad y pronostico de los pacientes. Al respecto, los autores insisten en que, en la practica clinica, las alteraciones cognitivas y psiquiatricas estan infradiagnosticadas y son poco consideradas en la investigacion clinica; no obstante, la evidencia, aunque escasa, apunta hacia posibles beneficios de los farmacos modificadores de la enfermedad y alternativas al tratamiento inhibidor selectivo de la recaptacion de serotonina. El abordaje de las subpoblaciones en esclerosis multiple y variantes de la enfermedad refuerza la importancia del diagnostico precoz y preciso para ofrecer a los pacientes un pronostico y un tratamiento mas seguros y personalizados. La esclerosis multiple pediatrica es idonea para estudiar factores de riesgo de la enfermedad, pero dada su baja prevalencia, se cuestionan los estudios prospectivos y se aboga por los estudios colaborativos.
- Published
- 2015
41. Evidence-Based Guidelines Magnims Consensus Guidelines on the Use of Mri in Multiple Sclerosis-Establishing Disease Prognosis and Monitoring Patients
- Author
-
Wattjes, M.P., Rovira, A., Miller, D., Yousry, T.A., Sormani, M.P., De Stefano, N., Tintore, M., Auger, C., Tur, C., Filippi, M., Rocca, M.A., Fazekas, F., Kappos, L., Polman, C., Barkhof, F., Montalban, X., Radiology and nuclear medicine, Neurology, NCA - Neuroinflamation, and NCA - Brain imaging technology
- Subjects
Cellular and Molecular Neuroscience ,Consensus ,Evidence-Based Medicine ,Multiple Sclerosis ,Neurology (clinical) ,Brain ,Disease Progression ,Humans ,Immunotherapy ,Magnetic Resonance Imaging ,Prognosis - Published
- 2015
42. Quantitative anti-MOG Serumtiter sind nicht prädiktiv für Krankheitsaktivität und -progression beim ersten Ereignis der Multiplen Sklerose – Ergebnisse einer ELISA-Studie
- Author
-
Menge, T, Lalive, PH, Tintore, M, von Büdingen, HC, Villoslada, P, and Genain, CP
- Published
- 2024
- Full Text
- View/download PDF
43. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica
- Author
-
Waters, P, Reindl, M, Saiz, A, Schanda, K, Tuller, F, Kral, V, Nytrova, P, Sobek, O, Nielsen, H H, Barington, T, Lillevang, S T, Illes, Z, Rentzsch, K, Berthele, A, Berki, T, Granieri, L, Bertolotto, A, Giometto, B, Zuliani, L, Hamann, D, van Pelt - T Gravesteijn, Elles, Hintzen, Rogier, Hoftberger, R, da Costa, C, Comabella, M, Montalban, X, Tintore, M, Siva, A, Altintas, A, Deniz, G, Woodhall, M, Palace, J, Paul, F, Hartung, HP, Aktas, O, Jarius, S, Wildemann, B, Vedeler, C, Ruiz, A, Leite, M I, Trillenberg, P, Probst, M, Saschenbrecker, S, Vincent, A, Marignier, R, Waters, P, Reindl, M, Saiz, A, Schanda, K, Tuller, F, Kral, V, Nytrova, P, Sobek, O, Nielsen, H H, Barington, T, Lillevang, S T, Illes, Z, Rentzsch, K, Berthele, A, Berki, T, Granieri, L, Bertolotto, A, Giometto, B, Zuliani, L, Hamann, D, van Pelt - T Gravesteijn, Elles, Hintzen, Rogier, Hoftberger, R, da Costa, C, Comabella, M, Montalban, X, Tintore, M, Siva, A, Altintas, A, Deniz, G, Woodhall, M, Palace, J, Paul, F, Hartung, HP, Aktas, O, Jarius, S, Wildemann, B, Vedeler, C, Ruiz, A, Leite, M I, Trillenberg, P, Probst, M, Saschenbrecker, S, Vincent, A, and Marignier, R
- Published
- 2016
44. A three-year, multi-parametric MRI study in patients at presentation with CIS
- Author
-
Rocca MA, Agosta F, Sormani MP, Fernando K, Tintore M, Korteweg T, Tortorella P, Miller DH, Thompson A, Rovira A, Montalban X, Polman C, Barkhof F, Filippi M, Tintoré M, Thompson AJ, Polman CH, Rocca, Ma, Agosta, F, Sormani, Mp, Fernando, K, Tintore, M, Korteweg, T, Tortorella, P, Miller, Dh, Thompson, A, Rovira, A, Montalban, X, Polman, C, Barkhof, F, Filippi, M, Tintoré, M, Thompson, Aj, Polman, Ch, Radiology and nuclear medicine, Neurology, and Neuroscience Campus Amsterdam 2008
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,Multiple Sclerosis ,Brain damage ,Grey matter ,Severity of Illness Index ,Central nervous system disease ,White matter ,Disability Evaluation ,Predictive Value of Tests ,Risk Factors ,Image Processing, Computer-Assisted ,medicine ,Humans ,Mass Screening ,Longitudinal Studies ,Retrospective Studies ,Clinically isolated syndrome ,medicine.diagnostic_test ,business.industry ,Multiple sclerosis ,Interferon beta-1a ,Brain ,Magnetic resonance imaging ,Syndrome ,Prognosis ,medicine.disease ,Magnetic Resonance Imaging ,medicine.anatomical_structure ,Neurology ,Disease Progression ,Female ,Neurology (clinical) ,Atrophy ,medicine.symptom ,business ,Nuclear medicine ,medicine.drug - Abstract
To define the extent of overall brain damage in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis (MS) and to identify non-conventional magnetic resonance (MR) metrics predictive of evolution to definite MS. Brain conventional and magnetization transfer (MT) MRI scans were obtained from 208 CIS patients and 55 matched healthy controls, recruited in four centres. Patients were assessed clinically at the time of MRI acquisition and after a median period of 3.1 years from disease onset. The following measures were derived: T2, T1 and gadolinium (Gd)- enhancing lesion volumes (LV), normalized brain volume (NBV), MTR histogram-derived quantities of the normal-appearing white matter (NAWM) and grey matter (GM). During the follow-up, 43 % of the patients converted to definite MS. At baseline, a significant inter-centre heterogeneity was detected for T2 LV (p = 0.003), T1 LV (p = 0.006), NBV (p < 0.001) and MTR histogram-derived metrics (p < 0.001). Pooled average MTR values differed between CIS patients and controls for NAWM (p = 0.003) and GM (p = 0.01). Gdactivity and positivity of International Panel (IP) criteria for disease dissemination in space (DIS), but not NAWM and GM MTR and NBV, were associated with evolution to definite MS. The final multivariable model retained only MRI IP criteria for DIS (p = 0.05; HR = 1.66, 95 % CI = 1.00–2.77) as an independent predictor of evolution to definite MS. Although irreversible tissue injury is present from the earliest clinical stages of MS, macroscopic focal lesions but not "diffuse" brain damage measured by MTR are associated to an increased risk of subsequent development of definite MS in CIS patients.
- Published
- 2008
45. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis
- Author
-
Ernst Wilhelm, Radue, William, H. Stuart, Peter, A. Calabresi, Christian, Confavreux, Steven, L. Galetta, Richard, A. Rudick, Fred, D. Lublin, Bianca, Weinstock Guttman, Daniel, R. Wynn, Elizabeth, Fisher, Athina, Papadopoulou, Frances, Lynn, Michael, A. Panzara, Alfred, W. Sandrock, For, the SENTINEL Investigators including F. Fazekas, Enzinger, C., Seifert, T., Storch, M., Strasser Fuchs, S., Berger, T., Dilitz, E., Egg, R., Deisenhammer, F., Decoo, D, Lampaert, J., Bartholome, E., Bier, J., Stenager, E., Rasmussen, M., Binzer, M., Shorsh, K., Christensen, M., Ravnborg, M., Soelberg Sørensen, P., Blinkenberg, M., Petersen, B., Hansen, H. J., Bech, E., Petersen, T., Kirkegaard, M., Finland:, J. Eralinna, Ruutiainen, J., Soilu Hänninen, M., Säkö, E., Laaksonen, M., Reunanen, M., Remes, A., Keskinarkaus, I., Moreau, T., Noblet, M., Rouaud, O., Couvreur, G., Edan, G., Lepage, E., Drapier, S., De Burghgraeve, V., Yaouanq, J., Merienne, M., Cahagne, V., Gout, O., Deschamps, R., Le Canuet, P., Moulignier, A., Vermersch, P., De Seze, J., Stojkovic, T., Griffié, G., Engles, Ferriby, D., Debouverie, M., Pittion Vouyouvitch, S., Lacour, J. C., Pelletier, J., Feuillet, L., Suchet, L., Dalecky, A., Tammam, D., Lubetzki, C., Youssov, K., Mrejen, S., Charles, P., Yaici, S., Clavelou, P., Aufauvre, D., Renouil Guy, N., Cesaro, P., Degos, F., Benisty, S., Rumbach, L., Decavel, P., Confavreux, C., Blanc, S., Aubertin, P., Riche, G., Brochet, B., Ouallet, J. C., Anne, O., Menck, S., Grupe, Guttman, Lensch, E., Fucik, E., Heitmann, S., Hartung, H. P., Schröter, M., Kurz, F. M. W., Heidenreich, F., Trebst, C., Pul, R., Hohlfeld, R., Krumbholz, M., Pellkofer, H., Haas, J., Segert, A., Meyer, R., Anagnostou, P., Kabus, C., Poehlau, D., Schneider, K., Hoffmann, V., Zettl, U., Steinhagen, V., Adler, S., Steinbrecher E. Rothenfusser Körber, A. Steinbrecher E. Rothenfusser Körber, Zellner, Baum, K., Günther, A., Bläsing, H., Stoll, G., Gold, R., Bayas, A., Kleinschnitz, C., Limmroth, V., Katsarava, Z., Kastrup, O., Haller, P., Stoeve, S., Höbel, D., Oschmann, P., Voigt, K., Burger, C. V., Israel:, O. Abramsky, Karusiss, D., Achiron, A., Kishner, I., Stern, Y., Sarove Pinhas, I., Dolev, M., Magalashvili, D., Pozzili, : C., Lenzi, D., Scontrini, A., Millefiorini, E., Buttinelli, C., Gallo, P., Ranzato, F., Tiberio, M., Perini, P., Laroni, Alice, Marrosu, M., Cocco P. Marchi, E. Cocco P. Marchi, Spinicci, G., Massole, S., Mascia, M., Floris, G., Trojano, M., Bellacosa, A., Paolicelli, D., Bosco Zimatore, G., Simone, I. L., Giorelli, M., Di Monte, E., Mancardi, GIOVANNI LUIGI, Pizzorno, M., Murialdo, A., Narciso, E., Capello, A., Comi, G., Martinelli, V., Rodegher, M., Esposito, F., Colombo, B., Rossi, P., Polman, C. H., Jasperse, M. M. S., Zwemmer, J. N. P., Nielsen, J., Kragt, J. J., Jongen, P. J. H., De Smet, E., Tacken, H., Frequin, S. T. F. M., Siegers, H. P., Mauser, H. W., Fernandez Fernandez, O., León, A., Romero, F., Alonso, A., Tamayo, J., Montalban, X., Nos, C., Pelayo, R., Tellez, N., Rio, J., Tintore, M., Arbizu, T., Romero, L., Moral, E., Martinez, S., Switzerland:, L. Kappos, Achtnichts, L., Wilmes, S., Turkey:, R. Karabudak, Kurne, A., Erdem, S., Siva, A., Saip, S., Altintas, A., Atamer, A., Eraksoy, M., Bilgili, F., Topcular, B., Giovannoni, G., Lim, E. T., Lava, N., Murnane, M., Dentinger, M., Zimmerman, E., Reiss, M., Gupta, V., Scott, T., Brillman, J., Kunschner, L., Wright, D., Perel, A., Babu, A., Rivera, V., Killian, J., Hutton, G., Lai, E., Picone, M., Cadivid, D., Kamin, S., Shanawani, M., Gauthier, S., Morgan, A., Buckle, G., Margolin, D., Weinstock Guttman, B., Kwen, P. L., Garg, N., Munschauer, F., Khatri, B., Rassouli, M., Saxena, V., Ahmed, A., Turner, A., Fox, E., Couch, C., Tyler, R., Horvit, A., Fodor, P., Humphries, S., Wynn, D., Nagar, C., O'Brien, D., Allen, N., Turel, A., Friedenberg, S., Carlson, J., Hosey, J., Crayton, H., Richert, J., Tornatore, C., Sirdofsky, M., Greenstein, J., Shpigel, Y., Mandel, S., Adbelhak, T., Schmerler, M., Zadikoff, C., Rorick, M., Reed, R., Elias, S., Feit, H., Angus, E., Sripathi, N., Herbert, J., Kiprovski, K., Qu, X., Del Bene, M., Mattson, D., Hingtgen, C., Fleck, J., Horak, H., Javerbaum, J., Elmore, R., Garcia, E., Tasch, E., Gruener, G., Celesia, G., Chawla, J., Miller, A., Drexler, E., Keilson, M., Wolintz, R., Drasby, E., Muscat, P., Belden, J., Sullivan, R., Cohen, J., Stone, L., Marrie, R. A., Fox, R., Hughes, B., Babikian, P., Jacoby, M., Doro, J., Puricelli, M., Rossman, H., Boudoris, W., Belkin, M., Pierce, R., Eggenberger, E., Birbeck, G., Martin, J., Kaufman, D., Stuart, W., English, J. B., Stuart, D. S., Gilbert, R. W., Kaufman, M., Putman, S., Diedrich, A., Follmer, R., Pelletier, D., Waubant, E., Cree, B., Genain, C., Goodin, D., Guarnaccia, J., Patwa, H., Rizo, M., Kitaj, M., Blevins, J., Smith, T., Mcgee, F., Honeycutt, W., Brown, M., Isa, A., Nieves Quinones, D., Krupp, L., Smiroldo, J., Zarif, M., Perkins, C., Sumner, A., Fisher, A., Gutierrez, Jacoby, R., Svoboda, S., Dorn, D., Groeschel, A., Steingo, B., Kishner, R., Cohen, B., Melen, O., Simuni, T., Zee, P., Cohan, S., Yerby, M., Hendin, B., Levine, T., Tamm, H., Travis, L. H., Freedman, S. M., Tim, R., Ferrell, W., Stefoski, D., Stevens, S., Katsamakis, G., Topel, J., Ko, M., Gelber, D., Fortin, C., Green, B., Logan, W., Carpenter, D., Temple, L., Sadiq, S., Sylvester, A., Sim, G., Mihai, C., Vertino, M., Jubelt, B., Mejico, L., Phillips, J. T., Martin, A., Heitzman, D., Greenfield, C. F., Riskind, P., Cabo, A., Paskavitz, J., Moonis, M., Bashir J. Brockington, K. Bashir J. Brockington, Nicholas, A., Slaughter, R., Archer S. Harik, R. Archer S. Harik, Haddad, N., Pippenger, M. A., Van den Noort, S., Thai, G., Olek, M., Demetriou, M., Shin, R., Calabresi, P., Rus, H., Bever, C., Johnson, K., Sheremata, W., Delgado, S., Sherbert, R., Herndon, R., Uschmann, H., Chandler, A., Markowitz, C., Jacobs, D., Balcer, L., Mitchell, G., Chakravorty, S., Heyman, R., Stauber, Z., Goodman, A., Segal, B., Schwid, S., Samkoff, L., Levin, M., Jacewicz, M., Menkes, D., Pulsinelli, W., Frohman, E., Racke, M., Hawker, K., Ulrich, R., Panitch, H., Hamill, R., Tandon, R., Dulaney, E., Simnad, V., Miller, J., Wooten, G. F., Harrison, M., Bowen, J., Doherty, M., Wundes, A., Garden, G. A., Distad, J., Kachuck, N., Berkovich, R., Burnett, M., Sahai, S., Bandari, D., Weiner, L., Storey, J. R., Beesley, B., Hart, D., Moses, H., Sriram, S., Fang, J., O'Duffy, A., Kita, M., Taylor, L., Elliott, M., Roberts, J., Jeffery, D., Maxwell, S., Lefkowitz, D., Kumar, S., Sinclair, M., Neurology, and NCA - Multiple Sclerosis and Other Neuroinflammatory Diseases
- Subjects
Adult ,Male ,medicine.medical_specialty ,Multiple Sclerosis ,Adolescent ,Relapsing-Remitting ,Placebo ,Antibodies, Monoclonal, Humanized ,Gastroenterology ,Antibodies ,Central nervous system disease ,Pharmacotherapy ,Natalizumab ,Multiple Sclerosis, Relapsing-Remitting ,pathology/therapy ,Drug Therapy ,Internal medicine ,Monoclonal ,Medicine ,Humans ,Immunologic Factors ,Humanized ,medicine.diagnostic_test ,business.industry ,Multiple sclerosis ,Patient Selection ,Interferon beta-1a ,Antibodies, Monoclonal ,Brain ,Magnetic resonance imaging ,Interferon-beta ,Middle Aged ,medicine.disease ,Magnetic Resonance Imaging ,Surgery ,Treatment Outcome ,Neurology ,therapeutic use ,Combination ,Drug Therapy, Combination ,pathology ,Female ,Neurology (clinical) ,Adolescent, Adult, Antibodies ,Humanized, Antibodies ,therapeutic use, Brain ,pathology, Drug Therapy ,Combination, Female, Humans, Immunologic Factors ,therapeutic use, Interferon-beta ,therapeutic use, Magnetic Resonance Imaging, Male, Middle Aged, Multiple Sclerosis ,pathology/therapy, Patient Selection, Treatment Outcome ,business ,medicine.drug - Abstract
The SENTINEL study showed that the addition of natalizumab improved outcomes for patients with relapsing multiple sclerosis (MS) who had experienced disease activity while receiving interferon beta-1a (IFNbeta-1a) alone. Previously unreported secondary and tertiary magnetic resonance imaging (MRI) measures are presented here. Patients received natalizumab 300 mg (n=589) or placebo (n=582) intravenously every 4 weeks plus IFNbeta-1a 30 microg intramuscularly once weekly. Annual MRI scans allowed comparison of a range of MRI end points versus baseline. Over 2 years, 67% of patients receiving natalizumab plus IFNbeta-1a remained free of new or enlarging T2-lesions compared with 30% of patients receiving IFNbeta-1a alone. The mean change from baseline in T2 lesion volume over 2 years decreased in patients receiving natalizumab plus IFNbeta-1a and increased in those receiving IFNbeta-1a alone (-277.5mm(3) versus 525.6mm(3); p0.001). Compared with IFNbeta-1a alone, add-on natalizumab therapy resulted in a smaller increase in mean T1-hypointense lesion volume after 2 years (1821.3mm(3) versus 2210.5mm(3); p0.001), a smaller mean number of new T1-hypointense lesions over 2 years (2.3 versus 4.1; p0.001), and a slower rate of brain atrophy during the second year of therapy (-0.31% versus -0.40%; p=0.020). Natalizumab add-on therapy reduced gadolinium-enhancing, T1-hypointense, and T2 MRI lesion activity and slowed brain atrophy progression in patients with relapsing MS who experienced disease activity despite treatment with IFNbeta-1a alone.
- Published
- 2010
46. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results
- Author
-
Comi, G, O'Connor, P, Montalban, X, Antel, J, Radue, Ew, Karlsson, G, Pohlmann, H, Aradhye, S, Kappos, L, Easton, Jd, Kesselring, J, Weinshenker, Bg, Laupacis, A, Zarbin, M, Calandra, T, Temkin, N, Dimarco, J, Hudson, Ld, Durcan, L, Bar Or, A, Duquette, P, Bernier, G, Freedman, M, Maclean, H, Costello, F, Gray, Ta, Hohol, M, Devonshire, V, Oger, J, Hashimoto, S, Sørensen, Ps, Datta, P, Faber Rod JC, Frederiksen, J, Knudsen, S, Petrenaite, V, Färkkila, M, Harno, H, Halavaara, J, Elovaara, I, Kuusisto, H, Palmio, J, Airas, L, Kaasinen, V, Laaksonen, M, Vermersch, P, Pelletier, J, Feuillet, L, Suchet, L, Mauch, E, Gunser, C, Oberbeck, K, Rieckmann, P, Buttmann, M, Klein, M, Ghezzi, A, Zaffaroni, M, Baldini, S, Mancardi, G, Cioli, F, Capello, E, Rodegher, M, Radaelli, M, Pozzilli, C, Onesti, Emanuela, Romano, Silvia, Czlonkowska, A, Litwin, T, Darda Ledzion, L, Kwiecinski, H, Golebiowski, M, Podlecka, A, Cunha, L, Sousa, L, Matias, F, Pedrosa, R, Almeida, M, Pena, Je, de Sá, J, Ferreira, J, Rosa, M, Arbizu, T, Carmona, O, Casado, V, Tintore, M, Pelayo, R, Arroyo, R, Bartolome, M, De las Heras, V, Casanova, B, Bosca, I, Fernandez, O, Leon, A, Romero, F, Izquierdo, G, Gamero, M, Garcia, Jm, Kuhle, J, Mehling, M, Achtnichts, L, Goebels, N, Skulina, C, Waskoenig, J, Bates, D, Nichols, P, Bendfeldt, K, de Vera, A, Gruenbauer, W., Ben Dahan, David, Centre de résonance magnétique biologique et médicale (CRMBM), Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), and Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Oral ,Adult ,Male ,medicine.medical_specialty ,Multiple Sclerosis ,Time Factors ,Adolescent ,Phases of clinical research ,Administration, Oral ,Kaplan-Meier Estimate ,Relapsing-Remitting ,administration /&/ dosage/adverse effects ,Placebo ,law.invention ,Pulmonary function testing ,03 medical and health sciences ,Disability Evaluation ,Young Adult ,0302 clinical medicine ,Multiple Sclerosis, Relapsing-Remitting ,Randomized controlled trial ,law ,Sphingosine ,Internal medicine ,Fingolimod Hydrochloride ,administration /&/ dosage/adverse effects/analogs /&/ derivatives ,medicine ,Humans ,Adverse effect ,business.industry ,Fingolimod ,Magnetic Resonance Imaging ,diagnosis/drug therapy/pathology ,Administration ,Oral, Adolescent, Adult, Disability Evaluation, Female, Humans, Immunosuppressive Agents ,administration /&/ dosage/adverse effects, Kaplan-Meier Estimate, Magnetic Resonance Imaging, Male, Multiple Sclerosis ,diagnosis/drug therapy/pathology, Propylene Glycols ,administration /&/ dosage/adverse effects, Sphingosine ,administration /&/ dosage/adverse effects/analogs /&/ derivatives, Time Factors, Treatment Outcome, Young Adult ,3. Good health ,Surgery ,Clinical trial ,Treatment Outcome ,Neurology ,Propylene Glycols ,030220 oncology & carcinogenesis ,Female ,Neurology (clinical) ,business ,030217 neurology & neurosurgery ,Immunosuppressive Agents ,medicine.drug - Abstract
In a 6-month, placebo-controlled trial, oral fingolimod (FTY720) 1.25 or 5.0 mg, once daily, significantly reduced MRI inflammatory activity and annualized relapse rate compared with placebo in patients with relapsing multiple sclerosis (MS). The objectives were to monitor the 36-month, interim efficacy and safety results of the ongoing extension of this study. In the extension (months 7—36), placebo-treated patients were re-randomized to either dose of fingolimod; fingolimod-treated patients continued at the same dose. During months 15—24, all patients receiving fingolimod 5.0 mg switched to 1.25 mg. Of the 250 patients who entered the extension study, 173 (69%) continued to month 36. Most patients were free from gadolinium-enhanced lesions (88—89%) or new T2 lesions (70—78%) at month 36. Patients receiving continuous fingolimod treatment had sustained low annualized relapse rates of 0.20—0.21, and 68—73% remained relapse-free at month 36. Over 36 months, nasopharyngitis (34%), headache (30%), fatigue (19%) and influenza (18%) were the most commonly reported adverse events. Pulmonary function remained stable and blood pressure was stable after an initial increase (3—5 mmHg) during the first 6 months of fingolimod treatment; serious adverse events included infections and skin cancer. The low MRI and clinical disease activity at 6 months were maintained at 36 months with fingolimod, which was generally well tolerated by most patients. The efficacy and safety of oral fingolimod are being further evaluated in a large phase III MS study programme.
- Published
- 2010
47. The best indication to early treat the clinically isolated syndrome based on the clinical onset. A Cochrane analysis
- Author
-
Marinella CLERICO, Versino, E., Contessa, G., Ripellino, P., Palace, J., Tintore, M., and Durelli, L.
- Published
- 2009
48. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study
- Author
-
O'Connor, P, Comi, G, Montalban, X, Antel, J, Radue, Ew, de Vera, A, Pohlmann, H, Kappos, L, Easton, Jd, Kesselring, J, Weinshenker, Bg, Laupacis, A, Zarbin, M, Calandra, T, Temkin, N, Dimarco, J, Hudson, Ld, Durcan, L, Bar Or, A, Duquette, P, Bernier, G, Freedman, M, Maclean, H, Costello, F, Gray, Ta, Hohol, M, Devonshire, V, Hashimoto, S, Sørensen, Ps, Datta, P, Faber Rod JC, Frederiksen, J, Knudsen, S, Petrenaite, V, Harno, H, Färkkila, M, Halavaara, J, Elovaara, I, Kuusisto, H, Palmio, J, Airas, L, Kaasinen, V, Laaksonen, M, Vermersch, P, Pelletier, J, Feuillet, L, Suchet, L, Mauch, E, Gunser, C, Oberbeck, K, Rieckmann, P, Buttmann, M, Klein, M, Ghezzi, A, Zaffaroni, M, Baldini, S, Mancardi, G, Cioli, F, Capello, E, Rodegher, M, Radaelli, M, Pozzilli, C, Onesti, Emanuela, Romano, Silvia, Czlonkowska, A, Litwin, T, Darda Ledzion, L, Kwiecinski, H, Golebiowski, M, Podlecka, A, Nojszewska, K, Cunha, L, Sousa, L, Matias, F, Pedrosa, R, Almeida, M, Pena, Je, de Sá, J, Ferreira, J, Rosa, M, Arbizu, T, Carmona, O, Casado, V, Tintore, M, Pelayo, R, Arroyo, R, Bartolome, M, De las Heras, V, Casanova, B, Bosca, I, Fernandez, O, Leon, A, Romero, F, Izquierdo, G, Gamero, M, Garcia, Jm, Kuhle, J, Mehling, M, Achtnichts, L, Goebels, N, Skulina, C, Waskoenig, J, Bates, D, Nichols, P, Bendfeldt, K, Karlsson, G, Burtin, P, Zubal, T., Oconnor, P., Comi, G., Montalban, X., Antel, J., Radue, E. W., De Vera, A., Pohlmann, H., Kappos, L., and Radaelli, M
- Subjects
Male ,Time Factors ,Administration, Oral ,Kaplan-Meier Estimate ,Gastroenterology ,Severity of Illness Index ,law.invention ,Immunosuppressive Agent ,Disability Evaluation ,Randomized controlled trial ,law ,Oral administration ,Sphingosine ,hemic and lymphatic diseases ,Multiple Sclerosi ,administration /&/ dosage ,Respiratory Function Test ,Incidence ,Middle Aged ,Fingolimod ,Propylene Glycol ,Magnetic Resonance Imaging ,Respiratory Function Tests ,Tolerability ,Administration ,Female ,Oral, Adolescent, Adult, Disability Evaluation, Double-Blind Method, Female, Humans, Immunosuppressive Agents ,administration /&/ dosage, Incidence, Kaplan-Meier Estimate, Magnetic Resonance Imaging, Male, Middle Aged, Multiple Sclerosis ,drug therapy/mortality, Propylene Glycols ,administration /&/ dosage, Respiratory Function Tests ,methods, Severity of Illness Index, Sphingosine ,administration /&/ dosage/analogs /&/ derivatives, Time Factors, Young Adult ,medicine.symptom ,Immunosuppressive Agents ,medicine.drug ,Human ,Oral ,Adult ,medicine.medical_specialty ,Multiple Sclerosis ,Time Factor ,Adolescent ,Placebo ,methods ,Lesion ,Young Adult ,Double-Blind Method ,Internal medicine ,administration /&/ dosage/analogs /&/ derivatives ,Severity of illness ,medicine ,drug therapy/mortality ,Humans ,business.industry ,Fingolimod Hydrochloride ,Surgery ,Clinical trial ,Propylene Glycols ,Neurology (clinical) ,business - Abstract
Objective:: To report the results of a 24-month extension of a phase II trial assessing the efficacy, safety, and tolerability of the once-daily oral sphingosine-1-phosphate receptor modulator, fingolimod (FTY720), in relapsing multiple sclerosis (MS). METHODS:: In the randomized, double-blind, placebo-controlled core study, 281 patients received placebo or FTY720, 1.25 or 5.0 mg/day, for 6 months. During the subsequent dose-blinded extension, patients assigned to placebo were re-randomized to either dose of FTY720; those originally assigned to FTY720 continued at the same dose. Patients receiving FTY720 5.0 mg were switched to 1.25 mg during the month 15 to month 24 study visits. RESULTS:: Of 281 patients randomized in the core study, 250 (89%) entered the extension phase, and 189 (75.6%) received treatment for 24 months. During the core study, FTY720 significantly reduced gadolinium-enhanced (Gd) lesions and annualized relapse rate (ARR) compared with placebo, with no differences between doses. During the extension phase, patients who switched from placebo to FTY720 showed clear reductions in ARR and lesion counts compared with the placebo phase; ARR and lesion counts remained low in patients who continued FTY720 treatment. After 24 months, 79 to 91% of patients were free from Gd lesions and up to 77% of patients remained relapse free. FTY720 was well tolerated; no new safety concerns emerged during months 7 to 24 compared with the 6-month core study. CONCLUSIONS:: Once-daily oral treatment with FTY720, 1.25 or 5.0 mg, for up to 2 years, was well tolerated and was associated with low relapse rates and lesion activity. © 2009 AAN Enterprises, Inc.
- Published
- 2009
49. IL- 17 and IL-22 producing increased in multiple sclerosis relapses are MBP-specific. A multi-centre longitudinal study
- Author
-
Durelli, Luca, Conti, Laura, Clerico, Marinella, Boselli, D., Contessa, G., Ripellino, P., Viglietta, E., Lapuma, D., Uccelli, A., Cavalla, P., Zaffaroni, M., Rinaldi, L., Comi, C., Novelli, Francesco, Clerico, M., Faggiano, F., Palace, J., Tintore, M., and Durelli, L.
- Published
- 2009
50. MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain
- Author
-
Seewann, A, Enzinger, C, Filippi, M, Barkhof, F, Rovira, A, Gass, A, Miller, Dh, Montalban, X, Thompson, A, Yousry, T, Tintore, M, DE STEFANO, Nicola, Palace, J, Rovaris, M, Polman, C, and Fazekas, F.
- Subjects
atypical multiple sclerosis ,magnetic resonance imaging ,magnetic resonance imaging, idiopathic inflammatory demyelinating disorders, atypical multiple sclerosis ,idiopathic inflammatory demyelinating disorders - Published
- 2008
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.